A221505 – Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

• Participant has/had histologically confirmed invasive carcinoma of the breast
• No prior radiation therapy to the chest, neck or axilla
• No active collagen vascular diseases, such as: systemic lupus erythematous, scleroderma, or dermatomyositis
• Participant must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 8 months after radiation
• Additional eligibility in protocol

• History of prior or concurrent contralateral invasive breast cancer; benign breast disease, LCIS or DCIS of contralateral breast
• Positive inked histologic margins from mastectomy pathology (no invasive cells at margin)
• For patients with diabetes, hemoglobin A1C test must have been performed =< 90 days prior to registration
• Additional exclusions in protocol

For more information go to: https://clinicaltrials.gov/ct2/show/NCT03414970